Drug Profile
Research programme: cancer therapeutics - Hanmi Pharmaceuticals
Alternative Names: BTK/JAK dual inhibitor - Hanmi; EGFR mutant selective inhibitors - Hanmi; IAP inhibitor - Hanmi; Inhibitors of apoptosis protein inhibitors - HanmiLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Inhibitor of apoptosis protein inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in South Korea
- 29 Jun 2011 Early research is ongoing in South Korea
- 09 Aug 2010 Early research in Cancer in South Korea (unspecified route)